Critical Care Research Group, The Prince Charles Hospital, Queensland, Australia; School of Medical Sciences, Griffith University, Queensland, Australia.
Critical Care Research Group, The Prince Charles Hospital, Queensland, Australia; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Australia.
Pharmacol Res. 2021 Jul;169:105631. doi: 10.1016/j.phrs.2021.105631. Epub 2021 Apr 24.
Heart failure is an inexorably progressive disease with a high mortality, for which heart transplantation (HTx) remains the gold standard treatment. Currently, donor hearts are primarily derived from patients following brain stem death (BSD). BSD causes activation of the sympathetic nervous system, increases endothelin levels, and triggers significant inflammation that together with potential myocardial injury associated with the transplant procedure, may affect contractility of the donor heart. We examined peri-transplant myocardial catecholamine sensitivity and cardiac contractility post-BSD and transplantation in a clinically relevant ovine model.
Donor sheep underwent BSD (BSD, n = 5) or sham (no BSD) procedures (SHAM, n = 4) and were monitored for 24h prior to heart procurement. Orthotopic HTx was performed on a separate group of donor animals following 24h of BSD (BSD-Tx, n = 6) or SHAM injury (SH-Tx, n = 5). The healthy recipient heart was used as a control (HC, n = 11). A cumulative concentration-effect curve to (-)-noradrenaline (NA) was established using left (LV) and right ventricular (RV) trabeculae to determine β-adrenoceptor mediated potency (-logEC [(-)-noradrenaline] M) and maximal contractility (Emax).
Our data showed reduced basal and maximal (-)-noradrenaline induced contractility of the RV (but not LV) following BSD as well as HTx, regardless of whether the donor heart was exposed to BSD or SHAM. The potency of (-)-noradrenaline was lower in left and right ventricles for BSD-Tx and SH-Tx compared to HC.
These studies show that the combination of BSD and transplantation are likely to impair contractility of the donor heart, particularly for the RV. For the donor heart, this contractile dysfunction appears to be independent of changes to β-adrenoceptor sensitivity. However, altered β-adrenoceptor signalling is likely to be involved in post-HTx contractile dysfunction.
心力衰竭是一种进行性疾病,死亡率高,心脏移植(HTx)仍然是金标准治疗方法。目前,供体心脏主要来源于脑死亡(BSD)患者。BSD 会激活交感神经系统,增加内皮素水平,并引发显著的炎症,这些因素与移植过程中潜在的心肌损伤一起,可能影响供体心脏的收缩性。我们在临床相关的绵羊模型中检查了 BSD 后和移植前供体心脏的儿茶酚胺敏感性和心脏收缩性。
供体绵羊接受 BSD(BSD,n=5)或假手术(无 BSD)程序(SHAM,n=4),并在心脏获取前监测 24 小时。在 BSD 后 24 小时,另一组供体动物进行原位 HTx,分别为 BSD-Tx(n=6)或 SHAM 损伤(SH-Tx,n=5)。健康的受体心脏用作对照(HC,n=11)。使用左(LV)和右心室(RV)小梁建立了到(-)去甲肾上腺素(NA)的累积浓度效应曲线,以确定β-肾上腺素能受体介导的效力(-logEC[(-)去甲肾上腺素] M)和最大收缩性(Emax)。
我们的数据表明,BSD 后以及 HTx 后,RV(而非 LV)的基础和最大(-)去甲肾上腺素诱导的收缩性降低,无论供体心脏是否暴露于 BSD 或 SHAM。与 HC 相比,BSD-Tx 和 SH-Tx 的左心室和右心室中(-)去甲肾上腺素的效力较低。
这些研究表明,BSD 和移植的结合可能会损害供体心脏的收缩性,特别是 RV。对于供体心脏,这种收缩功能障碍似乎与β-肾上腺素能受体敏感性的变化无关。然而,改变的β-肾上腺素能受体信号可能参与移植后的收缩功能障碍。